| | | | | | | | | | | Download |
|
| | ABSciex4000_Study9-1_Site19_Blinded & Blanks only_2013-09-22_19-22-11.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 48 | 9.1_19_Blinded | |
| | | ABSciex4000_Study9-1_Site19_CalCurves only_2013-09-22_12-52-27.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 750 | 44 | 9.1_19_CalCurves | |
| | | site32_study9.1_rep2-4_Blinded_2013-09-22_19-10-46.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 56 | 9.1_32_Blinded | |
| | | site32_study9.1_rep2-4_AtoQC_4_2013-09-21_19-43-47.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 750 | 54 | 9.1_32_CalCurves | |
| | | Site52_5500_Blindedsamples_2013-09-22_19-11-26.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 51 | 9.1_52_Blinded | |
| | | Site52_5500_Curves_2013-09-23_15-59-10.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 750 | 44 | 9.1_52_CalCurves | |
| | | Site54_Study9-1_blindedsamples_LH_083011_v1_2013-09-22_19-12-07.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 52 | 9.1_54_Blinded | |
| | | Site54_Study9-1_standardcurves_083011_v1_2013-09-21_20-30-30.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 750 | 44 | 9.1_54_CalCurves | |
| | | Study9p1_site_56A_5500_Blinded_20120425_Final_2013-09-22_19-12-41.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 24 | 9.1_56A_Blinded | |
| | | Study9p1_site_56A_5500_20120425_Final_2013-09-21_20-30-56.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 750 | 48 | 9.1_56A_CalCurves | |
| | | Study9-1_Site56B_Agilent6490_042612_Blinded_only_2013-09-22_13-27-58.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 49 | 9.1_56B_Blinded | |
| | | Study9-1_Site56B_Agilent6490_042612_CalCurves_only_2013-09-22_13-28-46.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 750 | 44 | 9.1_56B_CalCurves | |
| | | Study9_1_Site56C_Final_BLINDED_Annotated_110111_2013-09-22_19-14-32.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 752 | 48 | 9.1_56C_Blinded | |
| | | Study9_1_Site56C_Final_CURVE_Annotated_110111_2013-09-22_09-29-34.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 752 | 44 | 9.1_56C_CalCurves | |
| | | Site 65 Study9.1 All Blinded Samples_2013-09-22_19-15-56.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 24 | 9.1_65_Blinded | |
| | | Site 65 Study9.1 All Curves_2013-09-22_09-29-51.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 750 | 44 | 9.1_65_CalCurves | |
| | | Study9_1_Site73_Xevo_blinded_v01_2013-09-22_19-18-56.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 752 | 24 | 9.1_73A_Blinded | |
| | | Study9_1_Site73_Xevo_allcurves_v01_2013-09-22_09-31-31.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 752 | 44 | 9.1_73A_CalCurves | |
| | | Study9_Site73_blinded_01_2013-09-22_19-18-04.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 24 | 9.1_73_Blinded | |
| | | Study9_Site73_curve_01_2013-09-22_09-30-12.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 750 | 44 | 9.1_73_CalCurves | |
| | | 9-1_Site86a_Blinded_2013-09-22_19-20-25.zip | 2015-02-06 14:33:57 | 34 | 124 | 248 | 746 | 48 | 9.1_86A_Blinded | |
| | | 9-1_Site86a_CalCurve_2013-09-22_09-32-28.zip | 2015-02-06 15:03:14 | 34 | 124 | 248 | 746 | 43 | 9.1_86A_CalCurves | |
| | | Site86_Study9.1_all_blinded_with_blanks_(annotations_lost)_2013-09-22_13-14-52.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 68 | 9.1_86_Blinded | |
| | | Site86_Study9.1_all_curves_with_blanks_(annotations_lost)_2013-09-22_13-14-11.zip | 2015-02-06 15:03:14 | 34 | 125 | 250 | 750 | 76 | 9.1_86_CalCurves | |
| | | CPTACstudy9_Agilent_LH_BlindedRuns_2013-09-22_19-21-32.zip | 2015-02-06 14:33:57 | 34 | 125 | 250 | 750 | 52 | 9.1_90_Blinded | |
| | | CPTACstudy9_Agilent_LH_CalCurve_A1-J1_A4-J4_2013-09-22_09-39-30.zip | 2015-02-06 15:03:14 | 34 | 123 | 246 | 738 | 44 | 9.1_90_CalCurves | |
| | | Study9-2_site32_Blinded_2013-09-24_10-37-26.zip | 2015-02-06 15:34:11 | 34 | 125 | 365 | 1,095 | 57 | 9.2_32_Blinded | |
| | | Study9-2_site32_Calcurve_2013-09-23_15-53-23.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 44 | 9.2_32_CalCurves | |
| | | Site52_Study9-2_BlindedSamples_20121214_2013-09-24_10-39-36.zip | 2015-02-06 15:34:11 | 34 | 125 | 365 | 1,095 | 24 | 9.2_52_Blinded | |
| | | Site52_Study9-2_CalCurve_20121214_2013-09-23_15-43-39.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 44 | 9.2_52_CalCurves | |
| | | Site54_Study9-2_BlindedSamples_20120411_2013-09-24_10-40-12.zip | 2015-02-06 15:34:11 | 34 | 125 | 365 | 1,095 | 50 | 9.2_54_Blinded | |
| | | Site54_Study9-2_CalCurve_20120411_2013-09-23_16-05-34.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 44 | 9.2_54_CalCurves | |
| | | ABSciex_5500_Study9-2_Site56A_0622012_v2_Blinded_only_2013-09-24_10-48-51.zip | 2015-02-06 15:34:11 | 34 | 125 | 365 | 1,095 | 46 | 9.2_56A_Blinded_postDesalt | |
| | | preDS_Study9-2_Site56A_030813_v1_Blinded_only_2013-09-24_10-56-37.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,095 | 52 | 9.2_56A_Blinded_preDesalt | |
| | | ABSciex_5500_Study9-2_Site56A_0622012_v2_CalCurve_only2_2013-09-24_10-51-38.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 46 | 9.2_56A_CalCurves_postDesalt | |
| | | preDS_Study9-2_Site56A_030813_v1_CalCurve_only_2013-09-24_10-53-47.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 42 | 9.2_56A_CalCurves_preDesalt | |
| | | Study9-2_Site56B_postds_050112_FINAL_v2_Blinded_Only_2013-09-24_11-06-35.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,095 | 41 | 9.2_56B_Blinded_postDesalt | |
| | | Study9-2_preds_Site56B_022013_FINAL_Blinded_only_2013-09-24_11-14-37.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,095 | 51 | 9.2_56B_Blinded_preDesalt | |
| | | Study9-2_Site56B_postds_050112_FINAL_v2_CalCurves_Only_2013-09-24_11-00-21.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 45 | 9.2_56B_CalCurves_postDesalt | |
| | | Study9-2_preds_Site56B_022013_FINAL_CalCurves_only_2013-09-24_11-13-09.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 43 | 9.2_56B_CalCurves_preDesalt | |
| | | Study9_2_Site56C_LH15N_CurveFinal_Annotated_PlusBlanks_021113_Blinded_only_2013-09-24_11-20-55.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,098 | 49 | 9.2_56C_Blinded | |
| | | Study9_2_Site56C_LH15N_CurveFinal_Annotated_PlusBlanks_021113_CalCurves_only_2013-09-24_11-20-01.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,098 | 44 | 9.2_56C_CalCurves | |
| | | Site 65 Study9.2 Blinded 051612_2013-09-24_11-23-02.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,095 | 24 | 9.2_65_Blinded_postDesalt | |
| | | Site 65 Study9.2 Pre Blinded Final_2013-09-24_11-23-33.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,095 | 24 | 9.2_65_Blinded_preDesalt | |
| | | Site 65 Study9.2 All Curves 051612_2013-09-24_11-20-20.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 44 | 9.2_65_CalCurves_postDesalt | |
| | | Site 65 Study9.2 PRE Curves Final_2013-09-24_11-24-16.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 44 | 9.2_65_CalCurves_preDesalt | |
| | | Study9_2_Site73a_blinded_v01_2013-09-24_11-38-29.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,098 | 24 | 9.2_73A_Blinded | |
| | | Study9_2_Site73a_CalCurve_v01_2013-09-24_11-27-27.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,098 | 44 | 9.2_73A_CalCurves | |
| | | CPTAC_Study9_2_site73_blinded_v02_2013-09-24_11-37-57.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,095 | 34 | 9.2_73_Blinded | |
| | | CPTAC_Study9_2_site73_curves_v01_2013-09-24_11-26-06.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 44 | 9.2_73_CalCurves | |
| | | 9-2_Site86a_Blinded_2013-09-24_11-40-58.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,098 | 48 | 9.2_86A_Blinded | |
| | | 9-2_Site86a_CalCurve_2013-09-24_11-29-44.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,098 | 40 | 9.2_86A_CalCurves | |
| | | 9-2_Site86_Blinded_2013-09-24_11-39-08.zip | 2015-02-06 15:34:12 | 34 | 125 | 365 | 1,095 | 48 | 9.2_86_Blinded | |
| | | 9-2_Site86_CalCurve_2013-09-24_11-28-53.zip | 2015-02-06 16:11:47 | 34 | 125 | 365 | 1,095 | 40 | 9.2_86_CalCurves | |
| | | Mouse_HeavyGradient_C2C12matrix_2020-04-02_09-09-41.sky.zip | 2020-04-02 10:23:41 | 35 | 71 | 142 | 526 | 12 | Analysis of Linearity of Heavy Peptides | |
| | | 6Erbb2_3KRT19_iRT_20131120_cal_curve_20-2_2015-06-02_15-26-27.sky.zip | 2015-06-16 16:06:20 | 12 | 19 | 28 | 88 | 14 | calibration curve for extraction reproducibility (replicate 2) | |
| | | 6Erbb2_3KRT19_iRT_20131120_cal_curve_20-3_2015-06-02_15-35-28.sky.zip | 2015-06-16 16:06:33 | 12 | 19 | 28 | 88 | 14 | calibration curve for extraction reproducibility (replicate 3) | |
| | | 6Erbb2_3KRT19_iRT_20131120_cal01_2015-06-02_13-42-34.sky.zip | 2015-06-16 16:06:06 | 12 | 19 | 28 | 88 | 14 | calibration curve for HER2 quantification in entire cohort (replicate 1) | |
| | | 6Erbb2_3KRT19_iRT_20131120_cal02_2015-06-02_13-51-16.sky.zip | 2015-06-16 16:06:06 | 12 | 19 | 28 | 88 | 14 | calibration curve for HER2 quantification in entire cohort (replicate 2) | |
| | | 6Erbb2_3KRT19_iRT_20131120_cal03_2015-06-02_13-55-19.sky.zip | 2015-06-16 16:06:06 | 12 | 19 | 28 | 88 | 14 | calibration curve for HER2 quantification in entire cohort (replicate 3) | |
| | | Assay_PeptideSelection_2020-02-26_14-52-16.sky.zip | 2020-03-04 14:52:55 | 698 | 5,870 | 7,170 | 42,239 | 2 | Discovery Data for Peptide Selection | |
| | | 6Erbb2_3KRT19_iRT_20131120_samples_20-2_2015-06-02_15-28-52.sky.zip | 2015-06-16 16:06:20 | 12 | 19 | 28 | 88 | 27 | extraction reproducibility in a subset of 9 samples (extraction replicate 2) | |
| | | 6Erbb2_3KRT19_iRT_20131120_samples_20-3_2015-06-02_15-38-21.sky.zip | 2015-06-16 16:06:33 | 12 | 19 | 28 | 88 | 27 | extraction reproducibility in a subset of 9 samples (extraction replicate 3) | |
| | | 6Erbb2_3KRT19_iRT_20131120_samples1_2015-06-02_14-25-11.sky.zip | 2015-06-16 16:05:27 | 12 | 19 | 28 | 88 | 40 | HER2 quantification data in entire cohort (injection replicate 1) | |
| | | 6Erbb2_3KRT19_iRT_20131120_samples2_2015-06-02_14-37-13.sky.zip | 2015-06-16 16:05:27 | 12 | 19 | 28 | 88 | 40 | HER2 quantification data in entire cohort (injection replicate 2) | |
| | | 6Erbb2_3KRT19_iRT_20131120_samples3_2015-06-02_14-41-56.sky.zip | 2015-06-16 16:05:27 | 12 | 19 | 28 | 88 | 40 | HER2 quantification data in entire cohort (injection replicate 3) | |
| | | 20May2018_NewPrep_BlastsRhoTubes_2020-02-28_09-40-02.sky.zip | 2020-03-04 14:52:55 | 34 | 69 | 140 | 459 | 36 | In Vitro C2C12 experiment | |
| | | Mouse_StatinExperiment_2_2020-02-28_09-38-48.sky.zip | 2020-03-04 14:52:56 | 34 | 72 | 141 | 433 | 22 | In Vitro Statin Treatment of C2C12 Cells | |
| | | Analysis_04152019_Tissues_2020-02-28_09-36-44.sky.zip | 2020-03-04 14:52:56 | 38 | 67 | 131 | 467 | 32 | In Vivo Analysis of Mouse Tissue | |
| | | Tissue_10dinj_2020-02-28_09-44-33.sky.zip | 2020-03-04 14:52:56 | 33 | 46 | 92 | 339 | 63 | In Vivo Statin Treatment Experiment | |
| | | Tubulin_Ova_AspN_SIS_Results_20200203_NoiRT_Linearity_Processed_Cell culture.sky.zip | 2020-04-17 07:12:07 | 4 | 25 | 30 | 184 | 36 | Linearity and reproducibility in cell culture and Trichostatin A treatment of cells | |
| | | Tubulin_Ova_AspN_SIS_Results_20200203_NoiRT_Linearity_Processed_Spinal cord_Brain homogenate.sky.zip | 2020-04-17 07:12:07 | 4 | 25 | 30 | 180 | 19 | Linearity in brain homegenate and spinal cord along with unknown spinal cord estimation | |
| | | Erbb2_6_peptides_iRT_Pyro_linearity_2015-06-09_12-54-57.sky.zip | 2015-06-16 16:06:47 | 12 | 17 | 23 | 69 | 42 | linearity in P. furiosus background | |
| | | Erbb2_6_peptides_iRT_TN_linearity_2015-06-09_13-02-57.sky.zip | 2015-06-16 16:06:47 | 12 | 17 | 23 | 69 | 42 | linearity in TNBC background | |
| | | Erbb2_6_peptides_iRT_Pyro_LOQ_2015-06-09_12-50-05.sky.zip | 2015-06-16 16:07:06 | 12 | 17 | 23 | 69 | 18 | lower limit of quantification data | |
| | | MitoPreps_C2C12_Soleus_2020-02-28_09-44-19.sky.zip | 2020-03-04 14:52:56 | 34 | 69 | 135 | 408 | 35 | Mito Enrichments for Method Development | |
| | | 20170210_HCy_MRM_AKCMFCS_analysis01_2019-09-12_14-50-27.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 346 | 9 | Primary human keratinocyte conditioned media containing FCS_0 pg/mL - 1000 pg/mL cytokines spiked-in_No fractionation_MRM runs | |
| | | 20170201_HCy_MRM_AKCMFCS_analysis01_lvl1000_2019-09-12_14-41-51.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 354 | 10 | Primary human keratinocyte conditioned media containing FCS_1000 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170201_HCy_MRM_AKCMFCS_analysis01_lvl125_2019-09-12_14-39-48.sky.zip | 2019-09-14 16:21:40 | 24 | 82 | 82 | 354 | 10 | Primary human keratinocyte conditioned media containing FCS_125 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170201_HCy_MRM_AKCMFCS_analysis01_lvl250_2019-09-12_14-40-35.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 354 | 10 | Primary human keratinocyte conditioned media containing FCS_250 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170201_HCy_MRM_AKCMFCS_analysis01_lvl37-5_2019-09-12_14-38-01.sky.zip | 2019-09-14 16:21:40 | 24 | 82 | 82 | 354 | 10 | Primary human keratinocyte conditioned media containing FCS_37.5 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170201_HCy_MRM_AKCMFCS_analysis01_lvl500_2019-09-12_14-41-14.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 354 | 10 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170324_HCy_MRM_AKCMFCS_analysis01_lvl500_Repl1_2019-09-12_14-50-52.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 347 | 10 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_Reproducibility experiment_Day 1_Replicate 1_MRM runs | |
| | | 20170324_HCy_MRM_AKCMFCS_analysis01_lvl500_Repl2_2019-09-12_14-51-17.sky.zip | 2019-09-14 16:21:42 | 24 | 82 | 82 | 347 | 10 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_Reproducibility experiment_Day 1_Replicate 2_MRM runs | |
| | | 20170324_HCy_MRM_AKCMFCS_analysis01_lvl500_Repl3_2019-09-12_14-51-46.sky.zip | 2019-09-14 16:21:42 | 24 | 82 | 82 | 347 | 10 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_Reproducibility experiment_Day 1_Replicate 3_MRM runs | |
| | | 20170324_HCy_MRM_AKCMFCS_analysis01_lvl500_Repl4_2019-09-12_14-52-12.sky.zip | 2019-09-14 16:21:42 | 24 | 82 | 82 | 347 | 10 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_Reproducibility experiment_Day 1_Replicate 4_MRM runs | |
| | | 20170405_HCy_MRM_AKCMFCS_analysis01_lvl500_Repl1_2019-09-12_14-54-01.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 347 | 10 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_Reproducibility experiment_Day 2_Replicate 1_MRM runs | |
| | | 20170405_HCy_MRM_AKCMFCS_analysis01_lvl500_Repl2_2019-09-12_14-54-27.sky.zip | 2019-09-14 16:21:42 | 24 | 82 | 82 | 347 | 10 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_Reproducibility experiment_Day 2_Replicate 2_MRM runs | |
| | | 20170405_HCy_MRM_AKCMFCS_analysis01_lvl500_Repl3_2019-09-12_14-54-54.sky.zip | 2019-09-14 16:21:42 | 24 | 82 | 82 | 347 | 10 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_Reproducibility experiment_Day 2_Replicate 3_MRM runs | |
| | | 20170405_HCy_MRM_AKCMFCS_analysis01_lvl500_Repl4_2019-09-12_14-55-21.sky.zip | 2019-09-14 16:21:42 | 24 | 82 | 82 | 347 | 10 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_Reproducibility experiment_Day 2_Replicate 4_MRM runs | |
| | | 20170325_HCy_MRM_AKCMFCS_lvl500_Repl1-4_analysis01_2019-09-12_14-53-38.sky.zip | 2019-09-14 16:21:42 | 24 | 82 | 82 | 351 | 6 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_No fractionation_Reproducibility experiment_Day 1_Replicate 1-4_MRM runs | |
| | | 20170405_HCy_MRM_AKCMFCS_lvl500_Repl1-4_analysis02_2019-09-12_14-55-48.sky.zip | 2019-09-14 16:21:42 | 24 | 82 | 82 | 351 | 6 | Primary human keratinocyte conditioned media containing FCS_500 pg/mL cytokines spiked-in_No fractionation_Reproducibility experiment_Day 2_Replicate 1-4_MRM runs | |
| | | 20170201_HCy_MRM_AKCMFCS_analysis01_lvl75_2019-09-12_14-38-49.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 354 | 10 | Primary human keratinocyte conditioned media containing FCS_75 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170201_HCy_MRM_AKCMFCS_analysis01_lvl0_2019-09-12_14-35-27.sky.zip | 2019-09-14 16:21:40 | 24 | 82 | 82 | 354 | 10 | Primary human keratinocyte conditioned media containing FCS_No cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170210_HCy_MRM_AKCM_analysis01_2019-09-12_14-49-54.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 351 | 9 | Primary human keratinocyte conditioned media without FCS_0 pg/mL - 1000 pg/mL cytokines spiked-in_No fractionation_MRM runs | |
| | | 20170206_HCy_MRM_AKCM_analysis01_lvl1000_2019-09-12_14-48-10.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 350 | 10 | Primary human keratinocyte conditioned media without FCS_1000 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170206_HCy_MRM_AKCM_analysis01_lvl125_2019-09-12_14-46-44.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 350 | 10 | Primary human keratinocyte conditioned media without FCS_125 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170206_HCy_MRM_AKCM_analysis01_lvl250_2019-09-12_14-47-12.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 350 | 10 | Primary human keratinocyte conditioned media without FCS_250 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170206_HCy_MRM_AKCM_analysis01_lvl37-5_2019-09-12_14-45-50.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 350 | 10 | Primary human keratinocyte conditioned media without FCS_37.5 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |
| | | 20170206_HCy_MRM_AKCM_analysis01_lvl500_2019-09-12_14-47-45.sky.zip | 2019-09-14 16:21:41 | 24 | 82 | 82 | 350 | 10 | Primary human keratinocyte conditioned media without FCS_500 pg/mL cytokines spiked-in_High pH reversed-phase peptide fractionation_MRM runs | |